Neuberger Berman Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Neuberger Berman Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-100,000	Closed	-$2.39M	–	1660
2019 Q4	$2.39M	Sell	100,000 -10,000	-9%	-$276K	﹤0.01%	993
2019 Q3	$2.95M	Sell	110,000 -17,900	-14%	-$502K	﹤0.01%	935
2019 Q2	$3.47M	Buy	127,900 +57,900	+83%	+$1.82M	﹤0.01%	923
2019 Q1	$2.43M	Buy	+70,000	New	+$2.02M	﹤0.01%	944
2018 Q1	–	Sell	-23,514	Closed	-$1.15M	–	1783
2017 Q4	$1.15M	Buy	23,514 +500	+2%	+$25.3K	﹤0.01%	1158
2017 Q3	$1.24M	Buy	23,014 +18,343	+393%	+$1.08M	﹤0.01%	1094
2017 Q2	$262K	Buy	+4,671	New	+$187K	﹤0.01%	1451
2015 Q2	–	Sell	-30,200	Closed	-$1.15M	–	1642
2015 Q1	$1.15M	Buy	30,200 +8,281	+38%	+$284K	﹤0.01%	1191
2014 Q4	$620K	Sell	21,919 -1,950	-8%	-$54.2K	﹤0.01%	1311
2014 Q3	$603K	Buy	+23,869	New	+$629K	﹤0.01%	1336

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Neuberger Berman Group's PTLA Position: Q1 2020 in Review

Neuberger Berman Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 100,000 shares — an estimated $2.39M sold.

Neuberger Berman Group first reported a position in PTLA in Q3 2014 and held it in 10 quarters. The position peaked at $3.47M in Q2 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

Neuberger Berman Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Neuberger Berman Group sold 100,000 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $2.39M.
Neuberger Berman Group first reported a position in Portola Pharmaceuticals, Inc. in Q3 2014 and held it in 10 quarters.
Neuberger Berman Group's Portola Pharmaceuticals, Inc. position peaked at $3.47M in Q2 2019.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Neuberger Berman Group's 13F filing for Q1 2020, filed 14 May 2020.